Acurastem Incorporated
Pasadena, CA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 150 N Orange Grove Blvd #220, Pasadena, CA 91103, USA
- Website
- acurastem.com
- Founded
- 2016
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Quralis Corporation | Cambridge, MA | — |
| Formation Venture Engineering Foundry Inc. | Topsfield, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Bolden Therapeutics Inc. | Providence, RI | — |
| Adrx, Inc. | Thousand Oaks, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Microquin LTD | Cambridge, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Acurastem Inc., doing business as Acurastem, is a biotechnology company focused on developing treatments for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and additional indications. The company specializes in near to clinic, patient based therapeutics.
Through prime federal grant awards, Acurastem Inc. has received funding to support the development of novel antisense oligonucleotide treatments targeting genes implicated in ALS and FTD, such as UNC13A, SYF2, and PIKFYVE. Major funding has come from the National Institutes of Health National Institute on Aging, the National Institutes of Health National Institute of Neurological Disorders and Stroke, and the Defense Health Agency under programs focused on aging research, neurological disorders research, and military medical research and development. In total, Acurastem Inc. has been awarded over $15 million in federal grants from 2021-2023 to advance its ALS and FTD treatment pipeline. Additionally, Acurastem Inc. has received a federal subaward from Pennsylvania State University related to small molecule drug discovery for ALS.
Quick answers
Is Acurastem Incorporated registered in SAM.gov?
Yes. Acurastem Incorporated's SAM.gov registration is active through June 15, 2027.
What is Acurastem Incorporated's CAGE code?
Acurastem Incorporated's CAGE code is 7KRR1, and its Unique Entity ID (UEI) is EHEBD1K16MJ4.
What is Acurastem Incorporated's most recent federal award?
Acurastem Incorporated's most recent federal grant award is Late-stage development of a pikfyve antisense oligonucleotide treatment for FTD (HT94252311018), from Defense Health Agency, on September 15, 2023.
On GovTribe
See Acurastem Incorporated's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors